Pharmaceutical Product Development, Inc. (PPDI)
The Company is a global contract research organization providing drug discovery and development services, post-approval expertise and compound partnering programs.
Recs
Only 1 negative quarter in 12 and this stock is cheap
The major players pipelines need to be filled and they will soon be throwing the money at development
Recs
Recs
strategic partnership in china, no debt, good dividend... upbeat conference call
Recs
Showed up on a screen for solid 5 year growth with low debt, cash on hand and still at attractive P/E ratios.
Recs
Outsourcing will grow, Strong Financials, Leader in its field - Hold.
Recs
Just numbers PEG TT&FETM (Trailing 2 & Future Estimate 2 months of 1.35. Then again the mechanics of valuation escape me.
Recs
Very steady and stable financials. P/E ratio very far below industry average, good dividend. Good stable industry that will be there forever.
Seems very cheap compared to 52 week high. I say good for growth over the next year or so as the economy recovers.
Recs
Current 21.71, Sept 15 09. Limit 20.10
Recs
Skepticism on the stock is out of proportion to its long-term profit generating ability; it has industry leading margins, very strong BS, and outsourcing to CROs is increasing from Big Pharma.
Recs
no matter what the economy does, you gotta have your meds
Recs
Tracking the Royce Special Equity Fund.
Recs
5 Star, Small Cap- pays dividend
Recs
This one is extremely attractive stock with great entry point at this price. I think it has lot of downside protection, but at the same time tremendous upside. By the time next real bull market arrives, this one will be $65-$70
Recs
5-Star, good financials
Recs
Great upside, value has been beaten down
Recs
Decent stock (not great) that is trading below its value. It has much larger upside.
Recs
Me, I'm just following the crowd. A lot of smart people recommended it, and who am I to argue with success?
Recs
Outsourcing R&D will pick up again.
Recs
Very well run CRO struggling through industry consolidation and funding issues. Outsourcing is still a trend embraced by pharma development and growth will return here.
Recs
Someone on CAPS made an indepth report about this company's performance over the past 36 months. I did not understand most of his anaylsis, but others complemented him on his words of wisdom.
Seeing that a "Wise Old Fool" her on CAPS states that this will outpeform, I must agree with this, as the "Young Wipper Snapper Idiots" on CAPS got not a clue.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 74 1 2 3 4 Next »